151 related articles for article (PubMed ID: 38375893)
1. Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study.
Sartori M; Iotti M; Camporese G; Siragusa S; Imberti D; Bucherini E; Corradini S; Ageno W; Prandoni P; Ghirarduzzi A
Am J Hematol; 2024 May; 99(5):854-861. PubMed ID: 38375893
[TBL] [Abstract][Full Text] [Related]
2. Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study.
Donadini MP; Dentali F; Pegoraro S; Pomero F; Brignone C; Guasti L; Steidl L; Ageno W
Vasc Med; 2017 Dec; 22(6):518-524. PubMed ID: 28732457
[TBL] [Abstract][Full Text] [Related]
3. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
[TBL] [Abstract][Full Text] [Related]
5. Two years outcome of isolated distal deep vein thrombosis.
Sartori M; Migliaccio L; Favaretto E; Palareti G; Cosmi B
Thromb Res; 2014 Jul; 134(1):36-40. PubMed ID: 24713107
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
Forster R; Stewart M
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
[TBL] [Abstract][Full Text] [Related]
8. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study.
Dentali F; Pegoraro S; Barco S; di Minno MND; Mastroiacovo D; Pomero F; Lodigiani C; Bagna F; Sartori M; Barillari G; Mumoli N; Napolitano M; Passamonti SM; Benedetti R; Ageno W; Di Nisio M
J Thromb Haemost; 2017 Sep; 15(9):1757-1763. PubMed ID: 28639418
[TBL] [Abstract][Full Text] [Related]
9. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
11. Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study.
Schellong S; Ageno W; Casella IB; Chee KH; Schulman S; Singer DE; Desch M; Tang W; Voccia I; Zint K; Goldhaber SZ
Semin Thromb Hemost; 2022 Jun; 48(4):446-458. PubMed ID: 33971682
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
13. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
14. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
Franco L; Giustozzi M; Agnelli G; Becattini C
J Thromb Haemost; 2017 Jun; 15(6):1142-1154. PubMed ID: 28316124
[TBL] [Abstract][Full Text] [Related]
16. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for people with cancer and central venous catheters.
Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Crawford F
Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
[TBL] [Abstract][Full Text] [Related]
19. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
20. Pentasaccharides for the treatment of deep vein thrombosis.
Brandao GM; Junqueira DR; Rollo HA; Sobreira ML
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011782. PubMed ID: 29199766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
